| Ticker | CELU |
|---|---|
| ISIN | US1511902041 |
| Sector | Consumo básico |
| Mercado | NASDAQ |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural kille...
Celularity Inc. opera en el sector Healthcare, industria Biotechnology.